What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review

Abstract

BackgroundPatients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes.MethodsEligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies−2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders.ResultsTwenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively.ConclusionsThe available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.Electronic supplementary materialThe online version of this article (doi:10.1186/s12888-017-1325-z) contains supplementary material, which is available to authorized users.

Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin

“…Although there are associations between psychosis and several classical autoimmune disorders (see above), including neuropsychiatric lupus, the frequency of ANA and thyroid antibodies in the general population precludes their relevance in defining possible AP. Equally, psychotic features are not infrequent in patients with classical paraneoplastic syndromes, but they are seldom isolated and the utility of antibody testing in individuals with isolated psychiatric presentations remains unclear 74,75 .…”

SOX1 Antibody in a Patient With Serotonin Syndrome

“…SOX1 antibodies have been linked to neoplastic, paraneoplastic, and non-neoplastic conditions with varying degrees of neurological involvement. Onconeural antibodies, specifically anti-Yo and anti-RI, have been found in those with psychiatric disorders [ 16 , 17 ]. These antibodies can also cause neurological damage by showing affinity to various parts of the central nervous system, leading to dysfunction secondary to inflammation.…”

Anti-Neuronal Autoantibodies (Cell Surface and Onconeural) and Their Association With Natural Autoantibodies in Synthetic Cannabinoid-Induced Psychosis

“…Anti-Hu and anti-Yo antibodies were shown to induce neuronal and Purkinje-cell death in the hippocampal and cerebellar regions of rats ( 35 – 37 ). Case reports suggested that anti-Yo and anti-Ri onconeural antibodies may play a role in autoimmune processes in patients with psychiatric disease ( 6 , 38 , 39 ). Only one of our patients was positive for anti-Amp antibody, two patients had borderline result for anti-Rec, and four patients showed a borderline result for anti-Yo, anti-Hu, anti-SOX1, or anti-Tr antibodies.…”